Dyne Common Stock Total Equity vs Cash Analysis

DYN Stock

USD 29.69 0.04 0.13%

Dyne Therapeutics financial indicator trend analysis is much more than just examining Dyne Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Dyne Therapeutics is a good investment. Please check the relationship between Dyne Therapeutics Common Stock Total Equity and its Cash accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.

Common Stock Total Equity vs Cash

Common Stock Total Equity vs Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Dyne Therapeutics Common Stock Total Equity account and Cash. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Dyne Therapeutics' Common Stock Total Equity and Cash is 0.18. Overlapping area represents the amount of variation of Common Stock Total Equity that can explain the historical movement of Cash in the same time period over historical financial statements of Dyne Therapeutics, assuming nothing else is changed. The correlation between historical values of Dyne Therapeutics' Common Stock Total Equity and Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Total Equity of Dyne Therapeutics are associated (or correlated) with its Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash has no effect on the direction of Common Stock Total Equity i.e., Dyne Therapeutics' Common Stock Total Equity and Cash go up and down completely randomly.

Correlation Coefficient

0.18

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Cash

Cash refers to the most liquid asset of Dyne Therapeutics, which is listed under current asset account on Dyne Therapeutics balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Dyne Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Dyne Therapeutics account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Most indicators from Dyne Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Dyne Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.As of the 22nd of November 2024, Issuance Of Capital Stock is likely to grow to about 126.9 M, while Selling General Administrative is likely to drop about 29.8 M.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	1.1M	1.7M	1.7M	997.5K
Research Development	121.3M	142.8M	210.8M	221.3M

Reconciled Depreciation Research Development

Dyne Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt
Total Assets		0.8	0.96	0.96	0.88	0.93	0.2	0.78	0.9	0.65	1.0	0.44	0.67	-0.22	-0.34	0.69	0.49	0.33	0.82	-0.11	0.76	0.8	0.99	0.93	0.91	0.75
Short Long Term Debt Total	0.8		0.71	0.77	0.5	0.65	-0.03	0.99	0.78	0.72	0.78	0.54	0.72	-0.09	0.2	0.12	-0.1	0.23	1.0	0.2	0.34	0.54	0.86	0.65	0.84	0.82
Other Current Liab	0.96	0.71		0.97	0.87	0.95	0.23	0.7	0.92	0.52	0.97	0.33	0.53	-0.11	-0.44	0.75	0.59	0.25	0.72	-0.13	0.74	0.75	0.94	0.95	0.82	0.63
Total Current Liabilities	0.96	0.77	0.97		0.86	0.93	0.34	0.76	0.98	0.58	0.96	0.3	0.58	-0.1	-0.33	0.67	0.48	0.22	0.78	-0.1	0.74	0.72	0.94	0.93	0.88	0.73
Total Stockholder Equity	0.88	0.5	0.87	0.86		0.85	0.54	0.47	0.8	0.51	0.88	0.36	0.52	-0.34	-0.51	0.84	0.67	0.24	0.53	-0.38	0.95	0.75	0.79	0.85	0.8	0.44
Property Plant And Equipment Net	0.93	0.65	0.95	0.93	0.85		0.23	0.66	0.87	0.37	0.96	0.11	0.38	-0.16	-0.48	0.78	0.62	0.28	0.66	-0.08	0.79	0.78	0.91	1.0	0.74	0.69
Current Deferred Revenue	0.2	-0.03	0.23	0.34	0.54	0.23		-0.06	0.4	0.12	0.18	-0.05	0.1	-0.33	-0.12	0.36	0.21	-0.24	0.0	-0.53	0.62	0.22	0.08	0.23	0.28	-0.08
Net Debt	0.78	0.99	0.7	0.76	0.47	0.66	-0.06		0.77	0.63	0.77	0.45	0.63	-0.05	0.2	0.1	-0.1	0.21	0.99	0.26	0.32	0.51	0.85	0.66	0.78	0.82
Accounts Payable	0.9	0.78	0.92	0.98	0.8	0.87	0.4	0.77		0.59	0.89	0.27	0.59	-0.04	-0.23	0.57	0.37	0.16	0.79	-0.06	0.67	0.64	0.89	0.87	0.87	0.72
Cash	0.65	0.72	0.52	0.58	0.51	0.37	0.12	0.63	0.59		0.59	0.84	1.0	-0.28	0.14	0.18	-0.02	0.31	0.73	-0.19	0.34	0.51	0.67	0.37	0.88	0.59
Non Current Assets Total	1.0	0.78	0.97	0.96	0.88	0.96	0.18	0.77	0.89	0.59		0.39	0.6	-0.2	-0.38	0.71	0.53	0.32	0.79	-0.1	0.77	0.8	0.98	0.96	0.88	0.74
Non Currrent Assets Other	0.44	0.54	0.33	0.3	0.36	0.11	-0.05	0.45	0.27	0.84	0.39		0.82	-0.26	0.15	0.05	-0.07	0.2	0.54	-0.18	0.18	0.3	0.44	0.11	0.63	0.22
Cash And Short Term Investments	0.67	0.72	0.53	0.58	0.52	0.38	0.1	0.63	0.59	1.0	0.6	0.82		-0.27	0.11	0.2	0.01	0.39	0.73	-0.17	0.35	0.53	0.68	0.38	0.89	0.6
Net Receivables	-0.22	-0.09	-0.11	-0.1	-0.34	-0.16	-0.33	-0.05	-0.04	-0.28	-0.2	-0.26	-0.27		-0.01	-0.2	-0.01	0.07	-0.11	0.8	-0.43	-0.64	-0.16	-0.16	-0.26	0.01
Good Will	-0.34	0.2	-0.44	-0.33	-0.51	-0.48	-0.12	0.2	-0.23	0.14	-0.38	0.15	0.11	-0.01		-0.83	-0.92	-0.24	0.19	0.28	-0.53	-0.24	-0.26	-0.48	-0.1	-0.03
Common Stock Total Equity	0.69	0.12	0.75	0.67	0.84	0.78	0.36	0.1	0.57	0.18	0.71	0.05	0.2	-0.2	-0.83		0.95	0.24	0.14	-0.4	0.85	0.64	0.6	0.78	0.48	0.27
Common Stock Shares Outstanding	0.49	-0.1	0.59	0.48	0.67	0.62	0.21	-0.1	0.37	-0.02	0.53	-0.07	0.01	-0.01	-0.92	0.95		0.24	-0.08	-0.28	0.69	0.41	0.41	0.62	0.26	0.13
Short Term Investments	0.33	0.23	0.25	0.22	0.24	0.28	-0.24	0.21	0.16	0.31	0.32	0.2	0.39	0.07	-0.24	0.24	0.24		0.23	0.21	0.17	0.23	0.34	0.28	0.36	0.35
Non Current Liabilities Total	0.82	1.0	0.72	0.78	0.53	0.66	0.0	0.99	0.79	0.73	0.79	0.54	0.73	-0.11	0.19	0.14	-0.08	0.23		0.17	0.37	0.56	0.87	0.66	0.85	0.82
Inventory	-0.11	0.2	-0.13	-0.1	-0.38	-0.08	-0.53	0.26	-0.06	-0.19	-0.1	-0.18	-0.17	0.8	0.28	-0.4	-0.28	0.21	0.17		-0.44	-0.5	-0.02	-0.08	-0.15	0.26
Other Current Assets	0.76	0.34	0.74	0.74	0.95	0.79	0.62	0.32	0.67	0.34	0.77	0.18	0.35	-0.43	-0.53	0.85	0.69	0.17	0.37	-0.44		0.69	0.66	0.79	0.65	0.39
Other Stockholder Equity	0.8	0.54	0.75	0.72	0.75	0.78	0.22	0.51	0.64	0.51	0.8	0.3	0.53	-0.64	-0.24	0.64	0.41	0.23	0.56	-0.5	0.69		0.77	0.78	0.71	0.47
Total Liab	0.99	0.86	0.94	0.94	0.79	0.91	0.08	0.85	0.89	0.67	0.98	0.44	0.68	-0.16	-0.26	0.6	0.41	0.34	0.87	-0.02	0.66	0.77		0.91	0.91	0.82
Property Plant And Equipment Gross	0.93	0.65	0.95	0.93	0.85	1.0	0.23	0.66	0.87	0.37	0.96	0.11	0.38	-0.16	-0.48	0.78	0.62	0.28	0.66	-0.08	0.79	0.78	0.91		0.74	0.69
Total Current Assets	0.91	0.84	0.82	0.88	0.8	0.74	0.28	0.78	0.87	0.88	0.88	0.63	0.89	-0.26	-0.1	0.48	0.26	0.36	0.85	-0.15	0.65	0.71	0.91	0.74		0.75
Short Term Debt	0.75	0.82	0.63	0.73	0.44	0.69	-0.08	0.82	0.72	0.59	0.74	0.22	0.6	0.01	-0.03	0.27	0.13	0.35	0.82	0.26	0.39	0.47	0.82	0.69	0.75

Click cells to compare fundamentals

Dyne Therapeutics Account Relationship Matchups

Dyne Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	16.4M	353.3M	425.7M	306.3M	165.1M	156.8M
Short Long Term Debt Total	8.4B	3.4M	32.6M	30.5M	27.4M	26.0M
Other Current Liab	1.1M	7.5M	16.9M	13.6M	18.7M	17.8M
Total Current Liabilities	2.4M	11.0M	28.7M	28.1M	51.1M	48.5M
Total Stockholder Equity	14.0M	342.4M	368.2M	252.4M	91.3M	86.7M
Property Plant And Equipment Net	1.5M	1.9M	41.0M	38.4M	33.4M	31.7M
Net Debt	(14.6M)	(300.9M)	(168.2M)	(141.7M)	(94.2M)	(89.5M)
Accounts Payable	1.3M	3.4M	4.0M	5.3M	22.9M	21.8M
Cash	14.6M	300.9M	200.8M	172.1M	121.6M	115.5M
Non Current Assets Total	1.7M	8.0M	43.3M	50.3M	35.7M	33.9M
Non Currrent Assets Other	191K	3.8M	2.3M	9.6M	2.3M	2.2M
Cash And Short Term Investments	14.6M	345.3M	376.6M	256.0M	123.1M	116.9M
Common Stock Shares Outstanding	45.4M	14.4M	50.9M	52.0M	59.7M	56.7M
Liabilities And Stockholders Equity	16.4M	353.3M	425.7M	306.3M	165.1M	156.8M
Non Current Liabilities Total	42K	3.4M	28.7M	25.9M	22.7M	21.6M
Other Current Assets	127K	7.5M	11.6M	9.6M	6.3M	6.0M
Other Stockholder Equity	6.4M	421.6M	596.9M	649.5M	723.8M	687.6M
Total Liab	2.4M	11.0M	57.5M	54.0M	73.8M	70.1M
Property Plant And Equipment Gross	1.5M	1.9M	42.9M	42.0M	38.7M	36.7M
Total Current Assets	14.8M	345.3M	382.4M	256.0M	129.4M	122.9M
Accumulated Other Comprehensive Income	0.0	(27K)	(269K)	(571K)	(656.7K)	(689.5K)
Retained Earnings	(19.7M)	(79.2M)	(228.5M)	(396.6M)	(632.5M)	(664.1M)
Net Tangible Assets	(13.4M)	342.4M	368.2M	252.4M	290.2M	207.8M
Net Invested Capital	(13.4M)	342.4M	368.2M	252.4M	91.3M	86.7M
Net Working Capital	12.4M	338.1M	353.7M	237.5M	78.3M	74.4M
Property Plant Equipment	1.5M	1.9M	41.0M	38.4M	44.2M	46.4M

Pair Trading with Dyne Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dyne Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dyne Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Dyne Stock

0.75

VALN

Valneva SE ADR

Pair Corr

Moving against Dyne Stock

0.44	NXGLW	NexGel Warrant	Pair Corr
0.42	MLYS	Mineralys Therapeutics,	Pair Corr
0.34	KZR	Kezar Life Sciences	Pair Corr

The ability to find closely correlated positions to Dyne Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Dyne Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Dyne Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Dyne Therapeutics to buy it.

The correlation of Dyne Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Dyne Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Dyne Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Dyne Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Dyne Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dyne Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dyne Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dyne Therapeutics Stock:

How To Invest In Dyne

Details

Is Dyne Stock a good investment?

Details

What is Dyne Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.

You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dyne Therapeutics. If investors know Dyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.58)

Return On Assets

(0.40)

Return On Equity

(0.69)

The market value of Dyne Therapeutics is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dyne Therapeutics' market value can be influenced by many factors that don't directly affect Dyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Dyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Dyne Common Stock Total Equity vs Cash Analysis

Common Stock Total Equity vs Cash

Common Stock Total Equity vs Cash Correlation Analysis

Correlation Coefficient

Common Stock Total Equity

Cash

Dyne Therapeutics fundamental ratios Correlations

Dyne Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Dyne Therapeutics fundamental ratios Accounts

Pair Trading with Dyne Therapeutics

Moving together with Dyne Stock

Moving against Dyne Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Total Assets
Non Current Liabilities Total	+ 1.0	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Total Liab	+ 0.99	Total Assets
Net Debt	+ 0.99	Short Long Term Debt Total

Common Stock Shares Outstanding	- 0.92	Good Will
Common Stock Total Equity	- 0.83	Good Will
Other Stockholder Equity	- 0.64	Net Receivables
Other Current Assets	- 0.53	Good Will
Inventory	- 0.53	Current Deferred Revenue
Good Will	- 0.51	Total Stockholder Equity